Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
Learn more:Â UGA, Sanofi Pasteur develop new vaccine for H1N1 influenza
The Latest on: Flu vaccine
[google_news title=”” keyword=”flu vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Flu vaccine
- UAE flu vaccine for Umrah pilgrims: Cost, process explained as demand spikes at hospitalson March 29, 2024 at 4:33 am
Umrah is known as a minor pilgrimage to the holy city of Makkah that can be performed at any time of the year. With the Umrah season coinciding with the influenza season, health a ...
- Highly pathogenic avian influenza discovered in Texas and Kansason March 28, 2024 at 10:19 am
The USDA, FDA, and CDC announced on March 25, 2024, that highly pathogenic avian influenza (HPAI) was detected in cows in Texas and Kansa. Unpasteurized clinical samples of milk from the sick cattle ...
- APHIS Now Thinks Wild Birds Are to Blame for Highly Pathogenic Avian Influenza's Arrival on Four U.S. Dairieson March 28, 2024 at 9:32 am
The livestock industry continues to grapple with the first confirmed cases of Highly Pathogenic Avian Influenza (HPAI), more commonly known as bird flu, in cattle. On Monday, USDA's Animal and Plant ...
- Moderna Secures $750 Million in Funding to Develop a Flu Vaccine, Backed by Blackstone Life Scienceson March 28, 2024 at 4:30 am
Moderna announced that it had signed a $750 million financing agreement with Blackstone Life Sciences to develop an mRNA flu vaccine. Moderna stated that Blackstone Life Sciences will receive ...
- Moderna gets Blackstone backing for flu vaccine R&Don March 27, 2024 at 9:14 pm
An arm of the private equity firm pledged up to $750 million in funding for Moderna’s flu shot development, in exchange for milestones and royalties.
- Dairy Farmers Urged to Protect Against Wild Birds After Avian Influenza Found in Texas Cowson March 27, 2024 at 1:02 pm
Pennsylvania dairy farmers are being urged to practice good biosecurity after Texas dairy cows appear to have been sickened by avian influenza.
- Comparing Long-term Effects of Hospitalization for COVID-19 with Seasonal Influenzaon March 27, 2024 at 8:23 am
The following is a summary of "Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study," published in the March 2024 issue of Infectious Diseases by Xie ...
- Influenza on the downward slopeon March 26, 2024 at 5:12 pm
Influenza A and B is still making its rounds in Central Illinois, but the trend seems to be breaking as the positivity rate fell from 20% last week, to 18.6% this week.
- Influenza Newson March 26, 2024 at 5:00 pm
Feb. 29, 2024 — U.S. flu vaccines are likely to move from quadrivalent to trivalent due to a change in circulating influenza viruses, according to a new ... Feb. 19, 2024 — The prospect of the ...
- Influenza Vaccine for 2023-24 Season Is Effective Against Hospitalizationon March 26, 2024 at 6:20 am
In 2 MMWR reports, investigators provided interim estimates of 2023-2024 seasonal influenza vaccine effectiveness for the US as a whole and for California.
via Bing News